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http://dx.doi.org/10.1016/j.kjms.201Abstract This study was performed in order to determine the value of plasma osteopontin
(OPN) levels as a predictive factor of disease stage and recurrence in patients with bladder ur-
othelial carcinoma (UC). Data from 50 patients diagnosed to have bladder UC after transurethral
resection of bladder tumor (TURBT) from 2009 to 2010were evaluated prospectively. Blood tests
were performed before and after TURBT, and plasma OPN levels were measured using enzyme-
linked immunosorbent assay. Differences in OPN levels according to clinicopathologic variables
were analyzed statistically. Significant differences in plasma OPN levels were observed between
groups with and without muscle invasion (89.16 vs. 67.08 ng/mL, pZ 0.041). Comparison ac-
cording to tumor grade found no significant difference between high and low grade groups
(pZ 0.115). Mean plasma OPN levels decreased after TURBT without statistical significance
(pZ 0.571). Between groups with recurrence and those without recurrence, OPN levels of the
group with recurrence were higher without statistical significance (pZ 0.161). Comparison of
plasma OPN levels according to performance of radical cystectomy (RC) showed significant
differences; patients who underwent RC showed higher levels of plasma OPN (95.58 vs.
70.37 ng/mL, pZ 0.030). Comparison according to T stage after RC showed significant differ-
ences in OPN levels (T1: 67.45, T2: 86.60 and T3: 95.23 ng/mL, respectively, pZ 0.006). The
groupwith lymph node invasion showed significantly higher levels of OPN, compared to the group
without invasion (153.24 vs. 68.03 ng/mL, pZ 0.017). Preoperative plasma OPN levels corre-
lated to muscle invasion of bladder UC and pathological stage after RC.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Ae Hospital, Yeouidebang-Rho 53-22, Youngdeungpo-Gu, Seoul 150-960, South Korea.
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ological stage was assigned using TNM staging and gradingClinical stage and pathologic grade are usually the primary
prognostic factors in urothelial carcinoma (UC) of the
bladder [1]. However, even in patients with the same stage
or grade, there have been differences in the biological
potential [2,3]. Therefore, in order to provide further
prognostic information relevant to a particular UC of the
bladder in a specific patient, and to allow for more
appropriate therapies for individuals, novel biomarkers are
under continuous investigation [4]. Unfortunately, there
has been no reliable biomarker for diagnosis, prediction of
prognosis, or selection of appropriate treatment modalities
for UC of the bladder.
Osteopontin (OPN) is an integrin-binding glycoprotein
secreted by many normal tissues, and is found in blood,
urine, and breast milk [4]. OPN is involved in both normal
and pathological processes, and is thought to have a role in
promotion of tumor cell survival, invasiveness, and
progression [5,6]. Thus, increased OPN expression corre-
lates with tumorigenic transformation in a variety of
stromal and epithelial cell lines [7]. Clinical studies have
linked OPN to tumorigenesis, progression, and metastasis in
various human tumors, including breast, colon, gastric,
lung, ovarian, and prostate cancer [8]. In addition to its
expression in tissues, overexpression of OPN in the blood of
patients with a variety of other cancers, including breast,
colon, hepatic, and hormone-refractory prostate cancers
has been reported [9e11]. There is also the possibility of
correlation between plasma OPN levels and disease stage
and prognosis in patients suffering from UC of the bladder.
However, only a few studies have been conducted to
investigate the value of plasma OPN levels in UC of the
bladder [4]. We therefore hypothesized that, in patients
with UC of the bladder, plasma OPN level might be
predictive of disease stage, as well as recurrence of
disease. Objectives of this study were therefore to evaluate
this hypothesis in a pilot study for assessment of the value
of plasma OPN levels as a predictive biomarker for UC of
the bladder.
Materials and methods
The study protocol was reviewed and approved by the
institutional review board of the Korea University hospital
(IRB No.: GR0891-003). From January 2009 to March 2010,
blood samples were collected from 50 consecutive patients
(male: 44, female: 6) with UC of the bladder, before tran-
surethral resection of bladder tumor (TURBT), at the Korea
University Guro Hospital oncology clinic and Ansan Hospital
urology clinic. The inclusion criteria of the present study
limited the participants to those with newly diagnosed UC
of the bladder, and patients were excluded if they had
coexisting malignancy of another organ, past history of
urolithiasis, or a recent urinary tract infection, as OPN
levels might be affected by these conditions [8,12,13].
Patients who agreed to participate in this study were fol-
lowed up after TURBT, and monthly history and physical
examination, urinalysis, and urine cytology were included
in periodic follow-up. Abdominopelvic computed tomog-
raphy (AP-CT) and chest X-ray were performed every 6months. Cystoscopy was performed every 3 months. Path-
criteria [14,15], and clinical stage was also assigned using
reports from imaging studies, including chest X-ray, AP-CT,
and bone scans. Bladder recurrence was defined as tran-
surethral resection or biopsy of the bladder lesion
confirmed by pathology during follow-up periods after
initial TURBT. Extra-bladder recurrence included local
recurrence and distant metastasis (beyond the regional
lymph nodes) diagnosed by AP-CT and bone scan. Blood
tests for measurement of plasma OPN levels were per-
formed two timesdi.e., before TURBT and 3 months after
TURBT. Blood was centrifuged at 600g for 15 minutes in
order to obtain plasma. Plasma OPN levels were measured
using the enzyme-linked immunosorbent assay, as
described by previous investigators [9,10,16,17]. Plasma
OPN levels were analyzed statistically, as follows: paired t-
test for comparison of pre- and post-TURBT, independent t-
test for comparison according to pathologic variables
(muscle invasiveness, grading and lymph node invasion),
one-way analysis of variance for comparison according to
urine cytology and pathological T-stage, and KaplaneMeier
analysis for comparison of recurrence-free survival (RFS)
between subgroups; p< 0.05 was considered to indicate
statistical significance. The SPSS software version 14.0
(SPSS Inc., Chicago, IL) was used for statistical analysis.Results
The average age of patients was 63.2 years (range 30e89
years); the mean follow-up period was 19.9 months (range
12e26 months), and no deaths occurred during the study
period. Among 50 patients, 28 (56%) had more than one
comorbidity, including hypertension, diabetes, and cardio-
vascular disease. Twenty-four (48%) were smokers or ex-
smokers. Baseline characteristics of the investigated
patients are summarized in Table 1.
Comparison of plasma OPN levels according to the
results of urine cytology before TURBT showed no signifi-
cant difference between the four subgroups (negative,
atypical cell present, suspicious of malignancy and malig-
nant cell present group; pZ 0.497). Among 50 patients,
pathologic results for nine (18%) patients after TURBT
showed muscle invasion and there were significant differ-
ences in plasma OPN levels between the groups with and
without muscle invasion (pZ 0.041). With respect to tumor
grade after TURBT, pathologic results for 18 (36%) patients
showed that high-grade and plasma OPN levels did not
appear to differentiate between patients with high grade
and those with low grade tumors (pZ 0.115). Plasma OPN
levels showed a decreasing trend after TURBT, without
significant difference, compared with preoperative OPN
levels (pZ 0.571). After TURBT, 16 patients received
intravesical BCG instillation, and none of the patients
received intravesical chemotherapy. Recurrence after
TURBT was noted in 13 (26%) of these patients, and
between groups with recurrence and those without recur-
rence after TURBT, OPN levels of the group with recurrence
showed higher levels; however, no statistically significant
difference was observed between the two groups
(pZ 0.161). In the present study, 15 (30%) patients
Table 1 Baseline characteristics of the investigated
patients.
Variables (n)
Age (y) 63.2 12.2 (mean SD)
Sex
Male 44 (88%)
Female 6 (12%)
Smoking
(þ) 24 (48%)
(e) 26 (52%)
Comorbidities
>1a 28 (56%)
(e) 22 (44%)
Urine cytology
Negative 18 (36%)
Atypical cell present 9 (18%)
Suspicious of Malignancy 8 (16%)
Malignant cell present 15 (30%)
Grade
High 18 (40%)
Low 32 (60%)
pT stage
Ta 20 (40%)
T1 20 (40%)
Tis 1 (2%)
T2 8 (16%)
T3 1 (2%)
T4 0 (0%)
cN stage
N (e) 49 (98%)
N (þ) 1 (2%)
cM stage
M (e) 50 (100%)
M (þ) 0 (0%)
a Number of patients with more than one comorbidity, such as
hypertension, diabetes, cardiac disease, and cerebral disease.
Table 2 Clinicopathological variables in patients enrolled
in the study.
Variable (N ) Plasma OPN
levels (ng/mL)
(mean SD)
p
Sex 0.953
Male (44) 61.9 12.3
Female (6) 62.6 12.1
Urine Cytology 0.497a
Negative for malignancy 69.63 16.45
Atypical cell present 87.83 26.37
Suspicious of malignancy 71.18 22.80
Malignant cell present 86.34 54.28
Muscle invasionb 0.041
Invasive (9) 89.16 30.67
Non invasive (41) 67.08 37.08
Grade 0.115
High (18) 86.06 51.70
Low (32) 66.38 10.84
Recurrencec 0.161
þ (13) 81.19 37.45
 (37) 63.09 27.19
Radical cystectomyd 0.030
þ (15) 95.58 52.56
 (35) 70.37 24.98
T stagee 0.006a
T1 (4) 67.45 7.07
T2 (8) 86.60 17.71
T3 (3) 95.23 32.04
N stagee 0.017
N0 (10) 68.03 14.37
N1e3 (5) 153.24 86.87
OPNZ osteopontin.
Bold values are p < 0.05 with statistical significance.
a One-way ANOVA test.
b Pathologic results of initial transurethral resection of
bladder tumor (TURBT): invasive, T2; noninvasive, <T2.
c Recurrence after initial TURBT.
d Performing after initial TURBT.
e Pathologic results of radical cystectomy.
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period. Of the total, nine patients with muscle invasion
and three patients with high-grade T1 disease after TURBT
underwent immediate RC, and three patients with high-
grade T1 disease who received intravesical BCG instilla-
tion after TURBT eventually underwent RC after recurrence
of bladder TCC. Comparison of plasma OPN levels according
to performance of RC showed significant difference
(pZ 0.030); patients who underwent RC showed higher
levels. Comparison according to T stage after RC showed
significant differences in OPN levels (pZ 0.006); the higher
the T stage, the higher the OPN level. In addition, among 15
patients who underwent RC, five patients showed lymph
node metastases and they showed significantly higher levels
of OPN, compared to the group without lymph node inva-
sion (pZ 0.017). Results of our study are summarized in
Table 2.
The mean plasma OPN level of 50 patients was
77.48 33.76 ng/mL (range 31.31e246.84 ng/mL) and the
median was 67.20 ng/mL. We divided patients into two
groups according to the median: patients with lower OPN
levels (group I) and those with higher OPN levels (group II).Comparison of RFS rate using KaplaneMeier curves showed
nonsignificant difference in RFS between the two groups
(pZ 0.744) (Fig. 1).Discussion
OPN is an adhesive glycoprotein, first identified in bone,
and subsequently discovered in kidney, liver, brain, and
many cells of epithelial linings [18]. The glycoprotein
structure has multiple function domains [1]. The N-terminal
region binds to integrins, leading to cell attachment and
activation of matrix-degrading proteases [1]. The
OPNeintegrin complex mediates tumor cell invasion and
migration, induces angiogenesis, and activates osteoclasts,
facilitating bone metastases [1]. It also stimulates
Figure 1. KaplaneMeier curves showed nonsignificant
difference in recurrence-free survival between patients with
lower (group I) and higher (group II) plasma osteopontin (OPN)
levels (pZ 0.744).
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immunity [1]. The C-terminal region binds to CD44, acti-
vating the pathways of cell survival, chemotaxis, homing,
and adhesion [18,19]. According to Yoon et al. [20],
expression of OPN in UC of the bladder showed a significant
relationship with the invasiveness of the disease. In other
studies of the function of OPN in UC of the upper urinary
tract and their findings, Ke et al. [1] reported that higher
OPN expression was a potential biomarker for prediction of
patient survival.
Few studies on the value of plasma OPN in UC of the
urinary tract have been conducted, and only one pilot study
has reported on UC of the bladder. According to Ang et al.
[4] in their evaluation of the value of OPN in UC of the
bladder in 2005, OPN appears to be associated with disease
stage and to reflect tumor burden, as for other tumor
systems [9,10]. However, they did not limit participants to
newly diagnosed UC of the bladder and checked the plasma
OPN level at just one time point, without follow-up;
therefore, the prognostic value of OPN was not
adequately evaluated.
In the present study, we limited participants to newly
diagnosed UC of the bladder and checked the plasma OPN
level at more than one timedi.e., preoperatively and
postoperatively. In addition, we followed up the patients
for more than 1 year, in order to evaluate the association
between preoperative plasma OPN level and recurrence.
However, in the present study, several main limitations
exist, i.e., the relatively small number of patients and short
follow-up period, as well as the lack of investigation of
tissue OPN. In addition, the lack of control levels of plasma
OPN in the present study was also a limitation. Despite
these limitations, we were able to confirm that the possi-
bility and value of preoperative plasma OPN levels corre-
lated with the tendency to represent muscle invasion,
which has a decisive effect on the treatment strategy for
UC of the bladder. In addition, we found that preoperative
plasma OPN levels correlated with both the T stage andlymph node involvement in the pathologic results of RC,
demonstrating that the higher the preoperative plasma OPN
levels, the more severe the pathological and clinical stage.
With respect to the correlation between plasma OPN levels
and grade, although statistical significance was not
confirmed, our results showed a trend toward increase of
plasma OPN levels in the group with high grade bladder UC.
The detailed function of OPN in tumor progression is very
complex and is not yet completely known [1]. Many down-
stream signals, including P13K/Akt, NF-kB, MMP-2, and
EGFR, are regulated by OPN and have been known to play
important roles in tumor migration and invasion [19].
As well as the utility of plasma OPN to provide infor-
mation on prognosis, stratifying patients for adjuvant
therapies, prediction of recurrence and survival after
treatment is also valuable. In analysis of RFS between low
and high OPN groups, our results showed no significant
difference between the two groups. With respect to the
reason for this result, as mentioned above, the relatively
short follow-up period and small population sample could
contribute to the results. In addition, significant difference
was observed in plasma OPN levels according to muscle
invasion after TURBT; therefore, most of the high OPN
group patients tended to have a higher T stage, and, in
cases of higher T stage, immediate RC was preferred;
therefore, immediate RC could contribute to elimination of
the possibility of recurrence in the higher T stage group.
Although there was no significant difference in preopera-
tive plasma OPN levels according to the recurrence of
bladder UC in our study, if longer follow-up with more
patients is available, we can obtain more accurate infor-
mation on the value of preoperative plasma OPN as
a predictive marker for recurrence and survival in patients
of bladder UC. In addition, we expect the possibility of the
use of plasma OPN in monitoring responses to treatment in
patients with bladder UC. Although postoperative plasma
OPN levels were not checked in all patients and the
statistical significance was not established, plasma OPN
levels tended to decrease after surgery in our study;
therefore, if consecutive measurement of plasma OPN
levels after surgery and during regular follow-up is possible,
we can assess the changes in plasma OPN levels at the time
of recurrence and evaluate the value of the plasma OPN as
a monitoring tool for patients of bladder UC.Conclusion
Preoperative plasma OPN levels were correlated to muscle
invasion. In addition, plasma OPN levels appear to increase
with disease burden in bladder UC. The implications of
these findings may correlate with the value and usefulness
of plasma OPN as a promising marker for predicting risk and
clinical prognosis in bladder UC. Therefore, larger and more
extended studies of plasma OPN in patients with bladder UC
are needed.Acknowledgments
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